With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.110-70-3,N1,N2-Dimethylethane-1,2-diamine,as a common compound, the synthetic route is as follows.
Step. A: N-Methyl-N’-methyl-N’-t-butoxycarbonylethylenediamine A solution of 1 gram (4.58 mmole) of di-t-butyl-dicarbonate in 8 mL of CH2 Cl2 at 0 C. was treated with 0.98 mL (9.16 mmole) of N-methyl-N’-methylethylenediamine. After 20 min the cooling bath was removed and the mixture allowed to warm to 22 C. After 4 hours the mixture was concentrated in vacuo. The residue was purified by flash chromatography on 68 g silica gel eluding with 1 liter of 100:9:0.3 CH2 Cl2:MeOH: ammonia water, then 500 mL of 100:11:0.3 CH2 Cl2:MeOH: ammonia water to give 190 mg (22%) of a volatile oil.
110-70-3 N1,N2-Dimethylethane-1,2-diamine 8070, achiral-nitrogen-ligands compound, is more and more widely used in various.
Reference£º
Patent; Merck & Co., Inc.; US5344830; (1994); A;,
Chiral nitrogen ligands in late transition metal-catalysed asymmetric synthesis¡ªI. Addressing the problem of ligand lability in rhodium-catalysed hydrosilations
Nitrogen-Containing Ligands for Asymmetric Homogeneous and Heterogeneous Catalysis